M&A / Deals BioMarin acquires Amicus Therapeutics for $4.8bn Pharmaceutical TechnologyBioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.Rare DiseaseRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaceutical Technology BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal. Rare Disease Read full story Post navigation Previous: FDA approves AstraZeneca’s Saphnelo for SLENext: Boehringer/Zealand dual-acting drug causes 16.6% weight loss Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026